


REMARKS

The Specification has been amended to refer to the prior applications (37 CFR 1.78).
Claim 19 has been amended. Support for the amendment of claim 19 may be found, *inter alia*, on page 5, lines 26-27. Entry of this Amendment is respectfully requested.

4-(3-(2,6-Dimethylbenzyloxy)phenyl)-4-oxobutyric acid is metabolized in mice, rats, dogs and humans to 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid and 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid. The administration of 4-(3-(2,6-Dimethylbenzyloxy)phenyl)-4-oxobutyric acid to treat certain metabolic disorders is disclosed in WO 02/100341 (Wellstat Therapeutics Corp.).

Respectfully submitted,



Lewis J. Kreisler
Reg. No. 38522
Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794